Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alaunos Therapeutics, Inc. (TCRT) SEC filings page on Stock Titan provides direct access to the companys regulatory disclosures, including current reports, registration statements and financing-related documents. These filings show how Alaunos describes its business as combining T-cell receptor (TCR) cell therapy for solid tumors with a preclinical-stage obesity and metabolic health drug development program centered on a small molecule candidate.
Through its Forms 8-K, Alaunos reports material events such as strategic reprioritization steps, capital raises, changes in executive leadership, governance matters and listing status. Recent 8-Ks detail a registered direct offering of common stock and pre-funded warrants under a shelf registration statement on Form S-3, a private offering of Series A-2 Convertible Preferred Stock with dividend, voting and conversion terms, and a settlement and release agreement with The University of Texas M.D. Anderson Cancer Center regarding unpaid invoices under a research and development agreement. Other 8-Ks describe Nasdaq notices of non-compliance and subsequent confirmation that the company regained compliance, as well as stockholder approvals of amendments to increase authorized common stock and adjust capital structure.
Alaunos Form S-1 registration statement outlines its identity as a preclinical-stage obesity and metabolic health drug development company, while also summarizing its history as a clinical-stage oncology-focused cell therapy company and the August 2023 decision to wind down its TCR-T Library Phase 1/2 trial. The S-1 also explains an equity purchase agreement and related warrant that allow the company, at its discretion, to sell common stock to an institutional investor up to a specified aggregate amount.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, such as financing structures, conversion prices, dividend rights, share authorization changes and listing compliance updates. Users can quickly scan material agreements, capital markets transactions and corporate actions, and then open the full EDGAR documents for detailed review. This page is a central resource for understanding how Alaunos presents its strategy, risks, and capital structure in official SEC documents.
Alaunos Therapeutics (TCRT) filed a resale S-1 covering up to 327,740 shares of common stock to be offered from time to time by Mast Hill Fund, L.P. The registration includes up to 247,840 “Purchase Shares” issuable under a May 19, 2025 Equity Purchase Agreement and up to 79,900 “Warrant Shares” issuable upon exercise of a five-year warrant with a $4.00 exercise price.
Alaunos is not selling securities in this registration and will not receive proceeds from Mast Hill’s resales. The company may receive up to $25,000,000 from any future sales of common stock to Mast Hill under the purchase agreement and up to $319,600 if the warrant is exercised. Nasdaq rules cap issuance at 19.99% of pre-agreement outstanding shares (327,740 shares) unless stockholder approval or an allowed exception applies, and a 4.99% beneficial ownership limit restricts Mast Hill’s holdings.
The common stock trades on Nasdaq as “TCRT”; the last reported sale price was $3.07 on October 20, 2025. Shares outstanding were 2,321,829 as of October 20, 2025.
Alaunos Therapeutics, Inc. is registering conversion shares related to two recently issued preferred series and disclosing program and corporate updates. The company closed a Series A-1 Preferred offering on April 11, 2025 for $500,000 (stated value $1,000 per share) with an initial conversion price of $2.76 and cumulative 10% annual dividends payable in kind. The company closed a Series A-2 Preferred offering on June 24, 2025 for $850,000 with an initial conversion price of $4.49 and similar 10% dividends. Up to 444,560 common shares may be sold by selling stockholders, including conversion shares; Series A-1 includes a beneficial ownership cap of 4.99% (expandable to 9.99% with notice) while Series A-2 contains no similar cap. The filing also notes a prior strategic reprioritization and wind-down of the TCR-T Library Phase 1/2 trial and reports a 13% partial response rate and 87% disease control rate in TCR-T patients in earlier testing. Risks disclosed include regulatory, conversion dilution, liquidity and potential Nasdaq delisting concerns.
Alaunos Therapeutics, Inc. is amending a shelf registration to register common shares issuable upon conversion of its Series A-1 and Series A-2 Convertible Preferred Stock and related resale by certain investors. The company sold 500 shares of Series A-1 Preferred for $500,000 and 850 shares of Series A-2 Preferred for $850,000 in private subscriptions. Each preferred series carries a 10% per annum dividend payable in kind and is convertible into common stock at initial prices of $2.76 (A-1) and $4.49 (A-2), subject to adjustments. A-1 conversions are subject to a 4.99% beneficial ownership limitation (increasable to 9.99% with notice); A-2 has no similar limit. The prospectus allows resale of up to 772,302 common shares; conversions and resales may cause dilution and could pressure the market price. The filing also discloses prior clinical updates, including a TCR-T program wind-down announced August 14, 2023, and limited clinical activity with one partial response and several stable disease observations in early TCR-T studies.
Amendment No. 1 to Schedule 13D reports that PMGC Capital LLC and its parent PMGC Holdings Inc. have completed an exit from their position in Alaunos Therapeutics, Inc. The filing states PMGC LLC sold all of its common stock in open-market transactions between June 16, 2025 and August 22, 2025 at prices ranging from $1.92 to $4.53. Following settlement of the August 22 trades on August 25, 2025, the reporting persons no longer beneficially own any shares of the issuer. The amendment serves as a final amendment and an exit filing; no other new funds, legal proceedings, or retained holdings are reported.
Strategic EP, LLC reported beneficial ownership of 149,827 shares of Alaunos Therapeutics, Inc. common stock, equal to 6.8% of the 2,205,716 shares outstanding as of August 20, 2025. The filing excludes 62,299 shares issuable upon exercise of pre-funded warrants that contain exercise limits tied to ownership thresholds (4.99% or, at holder election, 9.99%). On August 26, 2025, the filer and the issuer entered a Standstill Agreement permitting Strategic EP to exceed the 4.99% limit up to 9.99% and the filer agreed to waive rights to engage in takeover-related activities or otherwise seek to influence control of the company.
Ferdinand Groenewald, identified as Vice President of Finance at Alaunos Therapeutics, Inc. (TCRT), reported transactions dated 08/18/2025. He acquired 10,775 shares of common stock and was granted an employee stock option for 4,000 shares with an exercise price of $2.32 and an expiration date of 08/17/2035. The option vests one-sixteenth of the underlying shares in equal quarterly installments beginning 11/18/2025, subject to continued service.
The Form 4 shows the shares and options are held directly after the transactions. The filing is signed by Mr. Groenewald on 08/20/2025. No additional compensation details or company valuation metrics are provided in this filing.
Holger Weis, Chief Executive Officer and Director of Alaunos Therapeutics, Inc. (TCRT), exercised employee stock options to acquire 13,676 shares on 08/18/2025. The exercised options carry a $2.32 per-share exercise price and are fully vested as of the transaction date, resulting in 13,676 shares beneficially owned by Mr. Weis following the transaction. The Form 4 was signed and dated 08/20/2025 by the reporting person. The filing shows an acquisition via option exercise rather than an open-market purchase and does not report any dispositions or other classes of securities.
Alaunos Therapeutics, Inc. reports that it has regained compliance with the continued listing requirements of the Nasdaq Capital Market. Nasdaq’s Listing Qualifications staff notified the company on August 19, 2025 that the matter is now closed.
The company had previously fallen out of compliance after reporting stockholders’ equity of $2.06 million in its Annual Report for the year ended December 31, 2024, below the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1). In its Quarterly Report for the period ended June 30, 2025, Alaunos reported stockholders’ equity of $3.66 million, which met the rule’s threshold and restored compliance.
Form 4 filing for Alaunos Therapeutics, Inc. (TCRT) discloses that director Robert W. Postma received new equity awards on July 3, 2025.
- Restricted stock units (RSUs): 4,050 shares of common stock granted at $0.00 cost and vested immediately, increasing his direct holding to 33,133 shares.
- Stock options: Option to purchase 6,400 shares at an exercise price of $5.00 per share, expiring July 3, 2035. One-twelfth of the option vests monthly starting July 3, 2025; any remaining unvested portion fully vests just before the 2026 annual meeting.
- Indirect holdings: 62,416 shares held through WaterMill Asset Management Corp. and 24 shares in a spouse’s IRA.
The transactions are incentive-based grants rather than market purchases or sales, so they do not immediately affect public float or cash flows. However, they modestly increase insider ownership and further align the director’s interests with shareholders.